Michael Thomas Heffernan - 15 Sep 2026 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Reporting relationship: Director
Issuer ticker: TRVI
Reported as of: 15 Sep 2026
Net transaction value: -$594,218
SEC form: 4
Accepted by SEC: 17 Sep 2026, 16:55:22 UTC
Prior SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Galletta, attorney-in-fact

Key filing fact

Michael Thomas Heffernan filed Form 4 for Trevi Therapeutics, Inc. (TRVI) on 17 Sep 2026.

Key facts

This page summarizes Michael Thomas Heffernan's Form 4 filing for Trevi Therapeutics, Inc. (TRVI).
7 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Sep 2026, 16:55.

Change

Previous filing in this sequence was filed on 17 Jun 2026.
Current net transaction value: -$594,218.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001448914 Primary reporting owner

Heffernan Michael Thomas

Relationship: Director
Address: C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN
Signature: /s/ Christopher Galletta, attorney-in-fact
Signature date: 17 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRVI transaction

Common Stock

Options Exercise

Transaction value
Shares: +18,421
Change %: +290%
Price: $3.04^*
Shares after: 24,772
Date: 15 Sep 2026
Ownership: Direct

TRVI transaction

Common Stock

Sale

Transaction value: $276,464
Shares: -18,321
Change %: -74%
Price: $15.09
Shares after: 6,451
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1, F2

TRVI transaction

Common Stock

Sale

Transaction value: $1,588
Shares: -100
Change %: -1.6%
Price: $15.88
Shares after: 6,351
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1

TRVI transaction

Common Stock

Options Exercise

Transaction value
Shares: +21,052
Change %: +331%
Price: $3.33^*
Shares after: 27,403
Date: 15 Sep 2026
Ownership: Direct

TRVI transaction

Common Stock

Sale

Transaction value: $316,166
Shares: -20,952
Change %: -76%
Price: $15.09
Shares after: 6,451
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRVI transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -18,421
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,421
Exercise price: $3.04
Footnotes: F3, F4

TRVI transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -21,052
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,052
Exercise price: $3.33
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F3

These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.

Footnote F4

These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027.

Footnote F5

These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.

Footnote F6

These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027.